StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
14
Publishing Date
2022 - 03 - 15
1
2022 - 02 - 15
1
2021 - 12 - 21
1
2021 - 12 - 07
1
2021 - 12 - 06
1
2021 - 10 - 19
1
2021 - 09 - 22
1
2021 - 08 - 12
1
2021 - 07 - 12
1
2021 - 06 - 25
1
2021 - 06 - 21
1
2021 - 05 - 26
1
2021 - 03 - 11
2
Sector
Health technology
14
Manufacturing
2
Tags
Agreement
12
Alliances
22
Antiviral
12
Application
9
Approval
16
Bioscience
10
Biotech
9
Biotech-bay
48
Biotech-beach
11
Breast cancer
22
Cancer
59
Chmp
11
Clinical-trials-phase-iii
14
Collaboration
23
Conference
14
Covid
14
Covid-19
16
Disease
20
Drug
25
Earnings
17
Events
20
Fda
21
Fda-approvals
10
Financial
23
Financial results
20
Genetown
12
Global
35
Growth
10
Health
13
Hepatitis
19
Hiv
41
Impact
9
Leukemia
10
License
13
Liver
11
Market
48
Money
9
N/a
225
People
19
Pharma
12
Pharmaceutical
10
Phase 2
9
Phase 3
9
Positive
13
Potential
10
Pre-clinical
9
Preclinical
10
Report
20
Research
54
Results
51
Sciences
30
Study
11
T-cell
32
Technology
9
Therapeutics
42
Therapy
52
Treatment
50
Trial
23
Trodelvy
15
Yescarta
14
Entities
Galmed pharmaceuticals ltd.
1
Gilead sciences, inc.
14
Nrx pharmaceuticals inc
2
Polypid ltd.
1
Urogen pharma ltd.
1
Symbols
AAPL
13
ABB
28
ABCL
11
ABT
38
ACN
10
ADBE
11
ADMP
17
ADTX
13
APDN
29
ARVL
57
BDX
25
BNTX
61
CSCO
12
CVAC
13
CVS
13
DGX
11
DHR
13
DOW
16
DVAX
41
FNCTF
16
GE
11
GENE
12
GILD
14
GOOG
17
GOOGL
17
GSK
34
HGEN
18
HON
30
HPQ
12
INO
15
JNJ
298
LH
11
LLY
62
MDT
17
MESO
16
MMM
12
MRK
21
MRNA
98
NRXP
38
NVAX
67
NVS
17
OCGN
18
OSUR
12
PFE
58
PHG
15
QDEL
18
QGEN
16
RDHL
20
REGN
17
SAP
22
SNY
128
SNYNF
43
SRNE
35
TAK
11
TAYD
22
TMO
36
TNXP
20
TOMDF
26
VIR
18
VXRT
20
Exchanges
Nasdaq
14
Crawled Date
2022 - 03 - 15
1
2022 - 02 - 15
1
2021 - 12 - 21
1
2021 - 12 - 07
1
2021 - 12 - 06
1
2021 - 10 - 19
1
2021 - 09 - 22
1
2021 - 08 - 12
1
2021 - 07 - 12
1
2021 - 06 - 25
1
2021 - 06 - 21
1
2021 - 05 - 26
1
2021 - 03 - 11
2
Crawled Time
07:00
2
09:00
1
10:00
1
11:00
1
12:00
1
13:00
1
13:15
1
14:00
3
15:00
1
15:15
1
16:00
1
Source
www.biospace.com
6
www.globenewswire.com
4
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Covid
symbols :
Gild
save search
Coronavirus (COVID-19) Current Therapy Market Sees Antiviral Drugs Accounting For A Large Number Of Treatments
Published:
2022-03-15
(Crawled : 16:00)
- prnewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
15.13%
|
O:
0.47%
H:
0.62%
C:
-0.18%
covid-19
viral drug
treatment
drug
covid
therapy
antiviral
NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full Enrollment
Published:
2022-02-15
(Crawled : 14:00)
- prnewswire.com
NRXP
5 d
|
$3.01
-0.99%
-1.0%
210K
|
Manufacturing
|
-0.33%
|
O:
1.66%
H:
9.15%
C:
-0.65%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
9.56%
|
O:
0.01%
H:
0.65%
C:
0.35%
covid-19
zyesami
aviptadil
health
als
covid
yes
enroll
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published:
2021-12-21
(Crawled : 11:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-7.62%
|
O:
0.0%
H:
0.17%
C:
-0.87%
covid-19
treatment
europe
risk
oxygen
covid
disease
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Published:
2021-12-07
(Crawled : 10:00)
- globenewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-3.68%
|
O:
-0.14%
H:
0.0%
C:
0.0%
europe
covid
covid-19
CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19
Published:
2021-12-06
(Crawled : 15:00)
- globenewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-3.75%
|
O:
-0.07%
H:
0.0%
C:
0.0%
approval
covid
chmp
covid-19
Gilead Sciences Announces Veklury® Donations to Help Address the Ongoing COVID-19 Crisis in Indonesia and Armenia
Published:
2021-10-19
(Crawled : 14:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
1.59%
|
O:
0.15%
H:
1.5%
C:
1.36%
covid
ongoing
Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients with COVID-19
Published:
2021-09-22
(Crawled : 14:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-6.66%
|
O:
0.47%
H:
0.15%
C:
-0.96%
covid
risk
covid-19
Global $9.9 Billion Remdesivir Markets, 2021-2026 with 2020 as the Base Year - Focus on SARS-CoV-2 (COVID-19), MERS-CoV, Ebola, SARS-CoV
Published:
2021-08-12
(Crawled : 13:15)
- prnewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-4.14%
|
O:
0.59%
H:
1.07%
C:
0.9%
covid
sars-cov-2
NRx Pharmaceuticals Announces Partnership with the Israel Institute for Biological Research to Complete Development and Commercialization of BriLife™ COVID Vaccine
Published:
2021-07-12
(Crawled : 15:15)
- prnewswire.com
NRXP
5 d
|
$3.01
-0.99%
-1.0%
210K
|
Manufacturing
|
-73.94%
|
O:
-2.09%
H:
31.85%
C:
-14.37%
URGN
|
$14.37
4.66%
4.45%
280K
|
Health Technology
|
-3.88%
|
O:
-0.74%
H:
0.74%
C:
0.2%
PYPD
|
$4.4
4.44%
3.6K
|
Health Technology
|
-48.06%
|
O:
4.35%
H:
0.0%
C:
-4.5%
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-0.96%
|
O:
0.93%
H:
1.22%
C:
-0.23%
GLMD
|
$0.3728
-0.41%
64K
|
Health Technology
|
-87.59%
|
O:
0.69%
H:
0.0%
C:
-2.74%
covid
israel
partnership
commercialization
vaccine
research
Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children
Published:
2021-06-25
(Crawled : 07:00)
- globenewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
-0.34%
|
O:
-0.06%
H:
1.28%
C:
1.1%
covid
treatment
fda
children
merge
authorized
emergency use authorization
Gilead’s Veklury® (Remdesivir) Associated With a Reduction in Mortality Rate in Hospitalized Patients With COVID-19 Across Three Analyses of Large Retrospective Real-World Data Sets
Published:
2021-06-21
(Crawled : 13:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
0.51%
|
O:
0.57%
H:
0.86%
C:
0.54%
covid
Satcher Health Leadership Institute At Morehouse School Of Medicine, With Support From Google.org And Gilead Sciences, Launches Health Equity Tracker To Study Racial Health Inequities Related To Covid-19
Published:
2021-05-26
(Crawled : 12:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
1.09%
|
O:
-0.06%
H:
0.32%
C:
0.25%
covid
health
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
Published:
2021-03-11
(Crawled : 09:00)
- biospace.com/
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
4.76%
|
O:
-0.63%
H:
0.83%
C:
-0.66%
covid
trial
Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Published:
2021-03-11
(Crawled : 07:00)
- globenewswire.com
GILD
|
$66.95
0.29%
0.28%
5.6M
|
Health Technology
|
4.76%
|
O:
-0.63%
H:
0.83%
C:
-0.66%
covid
ev
trial
Gainers vs Losers
75%
25%
Top 10 Gainers
MTTR
|
News
M
|
$4.78
174.71%
63.6%
72M
|
AGBA
|
$2.565
105.2%
51.27%
200M
|
Finance
MLEC
|
$2.44
74.29%
42.62%
78M
|
n/a
EDBL
|
News
|
$6.28
67.02%
40.13%
16M
|
ATGL
|
$2.91
48.81%
32.8%
180K
|
ZAPP
|
$0.2175
47.16%
32.05%
16M
|
n/a
ONFO
|
$0.6075
38.38%
27.74%
7.3M
|
n/a
VIVK
|
$1.48
38.32%
27.7%
530K
|
Professional, Scientific, and T...
MNTS
|
$0.5
35.69%
26.3%
4.8M
|
SDIG
A
|
$3.635
35.13%
26.0%
1M
|
Your saved searches
Save your searches and get alerts when important news are released.